written by reader The 60 minute cancel treatment

by daveandmelinda | November 15, 2017 11:36 pm

Dave Lashmet[1]’s new cancer breakthrough procedure using adaptive radiotherapy[2] is quite interesting. Does anyone know which company he is teasing with this pitch?

Endnotes:
  1. Dave Lashmet: https://www.stockgumshoe.com/tag/dave-lashmet/
  2. radiotherapy: https://www.stockgumshoe.com/tag/radiotherapy/

Source URL: https://www.stockgumshoe.com/2017/11/microblog-the-60-minute-cancel-treatment/


9 responses to “written by reader The 60 minute cancel treatment”

  1. daveandmelinda says:

    Sorry, I mean the 60 Minute cancer treatment

  2. JohnM says:

    Looks to me like Accuray (ARAY).

    This post is for information sharing only for your own due diligence process and is not intended and should in no way be construed as investment advice. It represents my personal observation and opinion only and my posts are covered under the SGS disclaimer and the disclaimer on the Dr. KSS dropbox. Biotech investing is high risk.

  3. Bernard says:

    They touted in their promotion that the company had $1B or more is sales, so probably not ARAY

  4. bearbear says:

    Check out VRAY instead. I think it is a closer bet. Stock spikes 12% today after yesterday’s webinar. Suspect this is the stock. There is also a report on the stock from Motley Fool on 3rd Nov 2017 that explains a spike of 17% then. The stock has recorded a good ride this year since hitting a low of below $3!

  5. paladin says:

    Moderator mentioned help in buying stock on foreign markets with subscription. Also stated major breakthrough results just published in last couple of days. Checked JAMA and NE and found nothing.

  6. Bobbi says:

    Found this:
    http://medicalphysicsweb.org/cws/article/research/70464
    Swedish company, article published 11/15, with link to original article which mentions four patients. http://iopscience.iop.org/article/10.1088/1361-6560/aa9517
    However, the moderator talked about 100% with the first four patients treated; the article doesn’t talk about patient outcomes, but proof-of-concept.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.